Subscribe

Shield Therapeutics plc (SHIEF)

USD0.08 +0.00 (+0.00%)
GB OTC Healthcare Drug Manufacturers - Specialty & Generic
Address Northern Design Centre NE8 3DF
Gateshead, GB
CEO Anders Lundstrom
Website shieldtherapeutics.com
IPO 2019-12-06
ISIN GB00BYV81293

Explore sections of this company profile

Also trades on London Stock Exchange · STX.L (GBp) Other OTC · SHIEF (USD)
Description

Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/Feraccru, offers an innovative, non-salt-based oral treatment specifically for adults suffering from iron deficiency, irrespective of whether anemia is present. Furthermore, the company is advancing PT20, a pioneering iron-based phosphate binder that has successfully concluded its pivotal Phase II trials for managing hyperphosphatemia in individuals with chronic kidney disease. This enterprise was founded in 2008 and maintains its headquarters in Gateshead, United Kingdom.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.08 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
320
Beta
1.78
Float Shares
403.46M
Free Float %
37.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +0.00% -52.35% -43.38% -11.21% -45.21% +135.29% -11.11% -89.83% -96.73% -96.73%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.08
Quality scores
Altman Z-Score
-4.65
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +57.9% ★ Q4'25: +692.6% (vs Q4'23)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +31.7% ★ Q4'25: +32.5% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -24.7% Q4'25: -45.9% (vs Q4'23)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -20.3% Q4'25: -15.2% (vs Q4'23)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -299.5% Q4'25: -502.1% (vs Q4'23)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    -2.7% ★ Q4'25: +43.3% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -3.29× Q4'25: -1.93× (vs Q4'23)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.88) × ERP
WACC = 63% × Ke + 37% × Kd (25.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.08
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
3 Rev. Ana.
1 EPS Ana. 		Dec 2027
3 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
2 Rev. Ana.
Revenue
304.0K
est: 354.6K (-14.3%)
637.0K
est: 669.3K (-4.8%)
11.88M
est: 11.69M (+1.7%)
719.0K
est: 2.93M (-75.5%)
10.39M
est: 9.38M (+10.8%)
1.52M
est: 1.51M (+0.3%)
4.55M
est: 8.43M (-46.1%)
13.09M
est: 13.85M (-5.5%)
32.18M
est: 25.73M (+25.1%)
50.81M
est: 37.11M (+36.9%)
56.40M
52.23M – 58.57M
+52.0% YoY
77.33M
67.23M – 92.64M
+37.1% YoY
88.21M
78.79M – 99.73M
+14.1% YoY
126.61M
113.09M – 143.16M
+43.5% YoY
EBITDA
-12.98M
est: -252.0K (-5,053.6%)
-25.08M
est: -475.6K (-5,172.6%)
-2.76M
est: -8.30M (+66.7%)
-9.26M
est: -2.08M (-344.6%)
1.12M
est: -6.66M (+116.8%)
-18.75M
est: -1.08M (-1,642.5%)
-24.55M
est: -5.99M (-309.6%)
-30.29M
est: -9.84M (-207.8%)
-21.26M
est: -19.77M (-7.5%)
-9.17M
est: -28.51M (+67.8%)
-43.33M
-45.00M – -40.12M
-52.0% YoY
-59.41M
-71.17M – -51.65M
-37.1% YoY
-67.76M
-76.62M – -60.52M
-14.1% YoY
-97.27M
-109.98M – -86.88M
-43.5% YoY
EBIT
-15.37M
est: -280.3K (-5,385.3%)
-28.37M
est: -529.1K (-5,262.5%)
-6.50M
est: -9.24M (+29.6%)
-11.89M
est: -2.32M (-412.7%)
-2.57M
est: -7.41M (+65.3%)
-26.87M
est: -1.20M (-2,144.4%)
-26.18M
est: -6.67M (-292.7%)
-31.36M
est: -10.95M (-186.5%)
-22.68M
est: -20.11M (-12.8%)
-10.31M
est: -29.00M (+64.4%)
-44.08M
-45.78M – -40.82M
-52.0% YoY
-60.44M
-72.40M – -52.54M
-37.1% YoY
-68.94M
-77.95M – -61.58M
-14.1% YoY
-98.96M
-111.89M – -88.39M
-43.5% YoY
Net Income
-15.02M
est: -126.69M (+88.1%)
-19.59M
est: -151.42M (+87.1%)
-1.79M
est: -6.66M (+73.1%)
-8.80M
est: -51.53M (+82.9%)
-3.58M
est: -3.52M (-1.7%)
-19.68M
est: -78.15M (+74.8%)
-49.79M
est: -73.81M (+32.5%)
-33.29M
est: -31.80M (-4.7%)
-27.18M
est: -23.53M (-15.5%)
-18.05M
est: -9.58M (-88.4%)
-414.0K
-484.4K – -356.6K
+95.7% YoY
5.80M
4.99M – 6.79M
+1,500.8% YoY
7.78M
6.70M – 9.11M
+34.2% YoY
—
— – —
-100.0% YoY
SGA
8.74M
est: 1.75M (+399.0%)
16.72M
est: 3.31M (+405.8%)
10.08M
est: 57.73M (-82.5%)
4.15M
est: 14.49M (-71.3%)
8.04M
est: 46.32M (-82.6%)
20.15M
est: 7.48M (+169.4%)
30.77M
est: 41.66M (-26.1%)
36.89M
est: 68.41M (-46.1%)
34.59M
est: 126.27M (-72.6%)
31.15M
est: 182.11M (-82.9%)
276.80M
256.30M – 287.44M
+52.0% YoY
379.51M
329.92M – 454.63M
+37.1% YoY
432.87M
386.64M – 489.43M
+14.1% YoY
621.35M
554.99M – 702.54M
+43.5% YoY
EPS
-0.14
est: -0.14 (-0.1%)
-0.17
est: -0.17 (-1.7%)
-0.02
est: -0.01 (-104.0%)
-0.07
est: -0.06 (-24.8%)
-0.02
est: 0.00 (-476.0%)
-0.09
est: -0.09 (-6.5%)
-0.21
est: -0.08 (-157.8%)
-0.05
est: -0.04 (-31.3%)
-0.03
est: -0.03 (-12.4%)
-0.02
est: -0.01 (-88.6%)
0.00
0.00 – 0.00
+95.7% YoY
0.01
0.01 – 0.01
+1,500.8% YoY
0.01
0.01 – 0.01
+34.2% YoY
—
— – —
-100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-26 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-12 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-8.87M
OE per share TTM
-0.01
Owner's Yield
-10.42%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-163.7K
Shares Outstanding
1.07B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Anders Lundstrom Chief Executive Officer & Executive Director 154.0K male
Christian Schweiger Co-Founder & Non Executive Director 51.0K —
Carol Akinola Head of Pharmacovigilance & Medical Information — female
Kate Armanetti Senior Director of People & Culture — —
Lucy Kate Huntington-Bailey General Counsel, Chief Compliance Officer & Company Secretary — female
Santosh Shanbhag Chief Financial Officer — male
Suzanne Wood Group HR Director — female
Andrew Hurley Chief Commercial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic